EMICIZUMAB IN PAEDIATRIC PATIENT WITH TYPE 3 VON WILLEBRAND DISEASE WITH INHIBITORS: FROM "PROPHYLAXIS" TO "PERIOPERATIVE MANAGEMENT"

被引：0
|
作者：
Luciani, M. [1 ]
Iavarone, S. [2 ]
Di Felice, G. [3 ]
De Vincentiis, G. C. [4 ]
Lamura, F. [5 ]
Perrotta, D. [6 ]
Massoud, M. [1 ]
机构：
[1] Bambino Gesu Pediat Hosp, Onco Hematol Cell & Gene Therapy & Hematopoiet Tr, Rome, Italy
[2] Sapienza Univ Rome, Dept Maternal Infantile & Urol Sci, Rome, Italy
[3] Bambino Gesu Pediat Hosp, Hemostasis Lab, Rome, Italy
[4] Bambino Gesu Pediat Hosp, Otorhinolaryngol Unit, Rome, Italy
[5] Bambino Gesu Pediat Hosp, Dept Pediat Onco Hematol & Transfus Med, Rome, Italy
[6] Bambino Gesu Pediat Hosp, Dept Anesthesia & Crit Care, Rome, Italy
来源：
HAEMOPHILIA | 2023年 / 29卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
PO228
引用
收藏
页码：151 / 151
页数：1
相关论文
共 50 条
  • [1] Efficacy of emicizumab in a pediatric patient with type 3 von Willebrand disease and alloantibodies
    Weyand, Angela C.
    Flood, Veronica H.
    Shavit, Jordan A.
    Pipe, Steven W.
    [J]. BLOOD ADVANCES, 2019, 3 (18) : 2748 - 2750
  • [2] Effectiveness of emicizumab in preventing life-threatening bleeding complications in type 3 von Willebrand disease with inhibitors: A paediatric report
    Cefalo, Maria Giuseppina
    Ronco, Francesca
    Di Felice, Giovina
    Rinelli, Martina
    Oriana, Vincenzo
    Massoud, Michela
    Merli, Pietro
    Luciani, Matteo
    [J]. HAEMOPHILIA, 2021, 27 (04) : E495 - E497
  • [3] Switch to pdVWF:pdFVIII concentrate for prophylaxis in a paediatric patient with Type 3 von Willebrand disease: a case report
    Berger, Claire
    Thouvenin, Sandrine
    Montmartin, Aurelie
    Noyel, Pauline
    Legendre, Coline
    Tardy-Poncet, Brigitte
    [J]. HEMATOLOGY, 2023, 28 (01)
  • [4] The potential role of emicizumab prophylaxis in severe von Willebrand disease
    Barg, Assaf A.
    Avishai, Einat
    Budnik, Ivan
    Brutman, Tamar Barazani
    Tamarin, Ilia
    Dardik, Rima
    Bashari, Dalia
    Misgav, Mudi
    Lubetsky, Aharon
    Lalezari, Shadan
    Livnat, Tami
    Kenet, Gili
    [J]. BLOOD CELLS MOLECULES AND DISEASES, 2021, 87
  • [5] Von Willebrand factor inhibitors developed in type 3 von Willebrand disease
    Megdiche, F.
    Kassar, O.
    Hdiji, S.
    Mbarek, L.
    Charfi, M.
    Elloumi, M.
    Kallel, C.
    [J]. HAEMOPHILIA, 2019, 25 : 87 - 87
  • [6] VON WILLEBRAND FACTOR INHIBITORS IN TYPE 3 VON WILLEBRAND DISEASE: CHALLENGES IN DIAGNOSIS
    Megdiche, F.
    Kassar, O.
    Krichen, I.
    Kallel, F.
    Ghorbel, M.
    Elloumi, M.
    Kallel, C.
    [J]. HAEMOPHILIA, 2020, 26 : 135 - 135
  • [7] Perioperative management of patients with von Willebrand disease
    O'Donnell, James S.
    Lavin, Michelle
    [J]. HEMATOLOGY-AMERICAN SOCIETY OF HEMATOLOGY EDUCATION PROGRAM, 2019, : 604 - 609
  • [8] Emicizumab in Type 3 von Willebrand Disease: Report of a Case with an Alloantibody and Literature Review
    Giuffrida, Anna C.
    Siboni, Simona M.
    Baronciani, Luciano
    Poli, Giovanni
    Gandini, Giorgio
    Peyvandi, Flora
    [J]. SEMINARS IN THROMBOSIS AND HEMOSTASIS, 2024,
  • [9] Abdominoplasty in a Patient With Type 3 von Willebrand Disease
    Mert, Sinan
    Kuhlmann, Constanze
    Hagen, Christine Sophie
    Kessler, Katharina
    Balubaid, Mohammed
    Giunta, Riccardo E.
    Wiggenhauser, Paul S.
    [J]. ANNALS OF PLASTIC SURGERY, 2024, 92 (01) : 133 - 136
  • [10] PROPHYLACTIC EMICIZUMAB-KXWH IN CHILDREN AND ADULTS WITH TYPE 3 VON WILLEBRAND DISEASE
    Vo, Kenny
    Braustein, Kenneth
    Michals, Jennifer
    Pawar, Anjali
    [J]. PEDIATRIC BLOOD & CANCER, 2021, 68 : S18 - S18
12345